Patents Assigned to F. Hoffmann-La Roche Inc.
  • Patent number: 12084491
    Abstract: The invention provides a method of treating, preventing or ameliorating Parkinson's disease with Prasinezumab.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: September 10, 2024
    Assignees: Prothena Biosciences Limited, F. Hoffmann-La Roche, Inc.
    Inventors: Gennaro Pagano, Wagner Zago
  • Patent number: 10968469
    Abstract: The present invention relates to the use of a protein as a hydroxylase, a host cell comprising the protein, the use of the protein or host cell in the production of hydroxy-pipecolic acid (HPA), a method of production HPA, methods of producing the protein, a mutant protein and a nucleic acid encoding the mutant protein and a vector comprising a nucleic acid encoding the protein.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: April 6, 2021
    Assignee: F. Hoffmann-La Roche, Inc.
    Inventors: Mara Boenitz-Dulat, Hans Iding, Dennis Wetzl, Alessa Hinzmann
  • Patent number: 10168326
    Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: January 1, 2019
    Assignee: F. HOFFMANN-LA ROCHE INC.
    Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel
  • Patent number: 9272031
    Abstract: The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the ?-A4 peptide/A?4. The present invention relates in particular to a mixture of antibodies comprising one or two glycosylated antigen binding sites with a glycosylated asparagine (Asn) in the variable region of the heavy chain, i.e. mixtures of isoforms of antibodies which comprise a glycosylated Asn in the variable region of the heavy chain (VH). Also disclosed are compositions or antibody preparations comprising the specifically glycosylated antibody isoforms. Furthermore, the pharmaceutical and diagnostic uses for these antibodies are provided.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 1, 2016
    Assignee: F. Hoffmann-La Roche Inc.
    Inventors: Hansruedi Loetscher, Walter Huber, Diana Schuhbauer, Karl Weyer, Manfred Brockhaus, Bernd Bohrmann, Hans Koll, Andreas Schaubmar, Kurt Lang
  • Patent number: 8841430
    Abstract: The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliverative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliverative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: September 23, 2014
    Assignee: F. Hoffmann-La Roche Inc.
    Inventors: Sébastien Couillard-Despres, Claudia Karl, Hans-Georg Kuhn, Ludwig Aigner
  • Patent number: 8815505
    Abstract: The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: August 26, 2014
    Assignee: F. Hoffmann-La Roche Inc.
    Inventors: Sébastien Couillard-Despres, Claudia Karl, Hans-Georg Kuhn, Ludwig Aigner
  • Patent number: 7947448
    Abstract: The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: May 24, 2011
    Assignee: F. Hoffmann-La Roche Inc.
    Inventors: Sebastien Couillard-Despres, Claudia Karl, Hans-Georg Kuhn, Ludwig Aigner